NXTC
NextCure, Inc.·Healthcare
6.07
13.533%(−0.95)
Close PriceLast Updated: — ET
52W L: $4.6052W H: $15.74
NXTC NEWS
globenewswire.com
May 7
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
BELTSVILLE, Md., May 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today provided a business update and reported first quarter 2026 financial results.
globenewswire.com
May 4
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
Dose optimization will initially be focused on evaluating SIM0505 in patients with platinum-resistant ovarian cancer (PROC) Phase 1 data readout to be presented at ASCO 2026 BELTSVILLE, Md. , May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co.
globenewswire.com
May 4
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
globenewswire.com
Apr 21
NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026
globenewswire.com
Apr 7
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
BELTSVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, today announced that the U.S. Food And Drug Administration (FDA) has granted Fast Track Designation for SIM0505 for the treatment of platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
globenewswire.com
Mar 31
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
BELTSVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd.
